Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

GuideUpdated 6 min read

Thymosin alpha-1 access: approved abroad, not in the US

Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and it is not on the 503A bulks list. What that means for access, forms, and thymalin.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer: outside a clinical trial, thymosin alpha-1 has no approved or compounding route in the United States today. It is approved as Zadaxin (thymalfasin) in more than 30 countries, but FDA has never approved it. [1] US compounding pharmacies lost their basis to make it when FDA placed it in 503A Category 2 in 2023, and the nomination has since been withdrawn, so it is not on the list of bulk substances pharmacies may compound. [2] [3]

This guide explains what "approved abroad" means for someone in the US, what the human evidence shows, the forms you will see marketed, and how thymosin alpha-1 differs from thymalin. It does not give dosing.

What is thymosin alpha-1?

Thymosin alpha-1 is a synthetic copy of a 28 amino acid peptide found in the thymus. It supports T cell maturation and function, and has been used for roughly four decades in hepatitis B and C, as a vaccine adjuvant, and in other infections. [1] Unlike most peptides in our catalog, it has randomized human trials, which is why our evidence grade for it is human RCT.

What the human trials show

The evidence is real but mixed, and it depends on the condition.

  • Chronic hepatitis B: in a randomized trial of 98 patients in Taiwan, complete viral response at 18 months occurred in 40.6% of patients in one treatment arm versus 9.4% of untreated controls, with no significant side effects. [4]
  • Severe sepsis, 2013: a single-blind trial of 361 ICU patients found 28 day mortality of 26.0% with thymosin alpha-1 versus 35.0% with standard care, a difference that did not reach statistical significance. [5]
  • Sepsis, 2025: the larger, double-blind, placebo-controlled phase 3 TESTS trial in 1,106 adults at 22 centers in China found no difference in 28 day mortality (23.4% versus 24.1%, hazard ratio 0.99), and no secondary or safety outcome differed significantly. [6]
  • Vaccine response: in a pilot study of patients on hemodialysis, it enhanced the immune response to a pandemic influenza vaccine and was well tolerated. [7]

The sepsis result is the one to weigh most. The smaller 2013 trial pointed to a benefit, and the larger, better-blinded 2025 trial did not confirm it. [5] [6] The immune function page puts these results next to other immune-targeted options.

Approved abroad but not in the US: what that means

FDA approval is country-specific. A drug's approval in another country does not make it lawful to sell or prescribe in the US, and FDA has not approved thymalfasin. [1]

That leaves three US routes that people ask about, and none of them works today.

1. A prescription for an approved product. There is no FDA approved thymosin alpha-1 product for a doctor to prescribe.

2. A compounded prescription. A 503A pharmacy can compound from a bulk substance only if it is part of an approved drug, has a USP monograph, or is on the 503A bulks list. [3] FDA placed thymosin alpha-1 in Category 2 in 2023, citing immunogenicity risk and a lack of safety information for compounded product. FDA's page, current as of April 22, 2026, now lists it among nominations that were withdrawn: out of Category 2, but with no path onto the bulks list. [2] It was not among the peptides the Pharmacy Compounding Advisory Committee reviewed in July 2026. [8] It is also not one of the six peptides in HHS's October 2026 draft enforcement discretion policy for compounding. [13] Our HHS peptide policy explainer lists what that policy covers.

3. Bringing it in from abroad. FDA states that in most circumstances it is illegal for individuals to import drugs for personal use, and specifically that a drug approved in another country but unapproved in the US is illegal to import. FDA staff may use discretion only in narrow situations, such as a serious condition with no effective treatment available in the US, under conditions FDA sets out. [9] We do not cover workarounds. If you have a serious condition, the right first step is a US specialist.

The route that does exist: clinical trials. ClinicalTrials.gov lists registered studies of thymalfasin, most of them in cancer, hepatitis B, and critical care, and most of the studies currently recruiting are in China. [10] Enrollment depends on each trial's criteria.

Our thymosin alpha-1 regulatory timeline records each FDA action, the thymosin alpha-1 cost page explains why there is no lawful US price, and the state legal guide covers how state rules interact with federal compounding law. For the general process with peptides that do have a lawful path, see how to get peptides prescribed.

Why US status and foreign approval diverge

Seeing a drug approved in dozens of countries and unavailable in the US can feel like a paperwork gap. It is more than that. US approval requires an application to FDA with the evidence FDA asks for, and a foreign approval does not substitute for it. [9] The evidence also depends on the use. The hepatitis B trial was positive, the largest sepsis trial was not, and many of the uses people ask about online, such as general immune support, have no randomized trial behind them. [4] [6] A foreign label for hepatitis B says nothing about those uses.

Thymosin alpha-1 supplement and nasal spray forms

Every trial described above used subcutaneous injection. [4] [6] We found no published study of thymosin alpha-1 taken by mouth or as a nasal spray, so there is no evidence that capsules, "supplements," or sprays deliver the peptide. Products sold for research use are not lawful for human use, and FDA's Category 2 concern about immunogenicity from impurities applies with more force to products no regulator has inspected. [2]

Thymalin vs thymosin alpha-1

The names are similar and both come from thymus research, but they are different products.

  • Thymosin alpha-1 is one defined, synthetic 28 amino acid peptide, approved as a drug in more than 30 countries, with randomized trials. [1]
  • Thymalin is a mixture of peptides extracted from calf thymus, registered as a drug in Russia. Its main human evidence is one randomized, placebo controlled trial in elderly people, which also tested a pineal extract in a separate group and reported lower eight-year mortality with thymalin (6.6% versus 13.6% with placebo). The trial is sparsely reported, comes from the institute that developed thymalin, and has never been independently replicated. [11] It has never been reviewed by FDA.

A third thymic peptide, thymulin, is covered in our thymosin alpha-1 vs thymulin comparison. And despite the shared name, thymosin alpha-1 is unrelated to thymosin beta-4, the protein behind TB-500; see thymosin alpha-1 vs TB-500 and our explainer on TB-500 vs thymosin beta-4.

Athletes and WADA

We record thymosin alpha-1's status on the WADA Prohibited List as unclear. [12] Athletes should check with their anti-doping organization before using any unapproved substance.

What's actually offered, and what that means for you

FDA has found an online seller offering thymosin alpha-1 anyway. [14]

What that means for you

  • A pharmacy that compounds thymosin alpha-1 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [15] [16]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [17]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [18]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [19] [20]

If you're going ahead anyway

Each step is on the thymosin alpha-1 page: check the pharmacy's license, what a legitimate prescription and consult look like, why this is safer than a research-use-only product, and questions to ask. These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound thymosin alpha-1, with or without a prescription. [3]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Frequently asked questions

Is thymosin alpha-1 FDA approved?

No. It is approved as Zadaxin (thymalfasin) in more than 30 countries, mainly for chronic hepatitis B and as an immune adjuvant, but FDA has never approved it. [1]

Can a US compounding pharmacy make thymosin alpha-1?

Not lawfully today. FDA placed it in 503A Category 2 in 2023. Its nomination has since been withdrawn, so it is no longer in Category 2, but it is not on the 503A bulks list and has no active nomination, which leaves a 503A pharmacy no federal basis to compound it. [2] [3]

Can I bring Zadaxin back from another country?

FDA states that a drug approved in another country but unapproved in the US is illegal to import, and that FDA staff consider exceptions only in narrow circumstances, such as a serious condition with no effective treatment available in the US. Talk to a US clinician before considering it. [9]

What is the difference between thymalin and thymosin alpha-1?

Thymosin alpha-1 is a single defined 28 amino acid peptide made synthetically. Thymalin is a peptide mixture extracted from calf thymus and registered in Russia. Its main human evidence is one sparsely reported randomized, placebo controlled trial from the institute that developed it, which has never been independently replicated. [1] [11]

Sources

Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.

  1. [1]Camerini R, Garaci E. Historical review of thymosin alpha 1 in infectious diseases. Expert Opin Biol Ther 2015PubMed 26098768, 2015
  2. [2]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA, 2026
  3. [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  4. [4]Chien RN et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998PubMed 9581695, 1998
  5. [5]Wu J et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 2013PubMed 23327199, 2013
  6. [6]Wu J et al. The efficacy and safety of thymosin alpha 1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ 2025PubMed 39814420, 2025
  7. [7]Carraro G et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine in hemodialyzed patients: a pilot study. Vaccine 2012PubMed 22178096, 2012
  8. [8]FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, MOTS-c, DSIP, semax, epitalon)FDA, 2026
  9. [9]FDA: Personal importation (drugs approved in another country but unapproved in the US), accessed 2026-09-23FDA, 2026
  10. [10]ClinicalTrials.gov: registered studies of thymalfasin (thymosin alpha-1), searched 2026-09-232026

More from the blog